Top 50 Biotech Startup Investors in Denmark (August 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Novo Holdings
VC Fund
|
33 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $9.9M–$135M |
|
BioInnovation Institute
VC Fund
|
28 | Denmark, Germany, Switzerland | Convertible Note, Pre-Seed, Seed | Biotechnology, Medical, Health Care | $495k–$5.2M |
|
Export and Investment Fund
VC Fund
|
20 | Denmark, United States, United Kingdom | Seed, Series A | Software, Biotechnology, Health Care | $457k–$43M |
|
Vaekstfonden
VC Fund
|
18 | Denmark, United States, United Kingdom | Seed, Pre-Seed | Software, Information Technology, SaaS | $384k–$5.3M |
|
Seed Capital
VC Fund
|
9 | Denmark, United States, United Kingdom | Seed, Series A | Software, Health Care, SaaS | $549k–$17M |
|
PSV
VC Fund
|
7 | Denmark, United States, United Kingdom | Seed, Pre-Seed | Software, Information Technology, SaaS | $353k–$4.6M |
|
Gilde Healthcare
VC Fund
|
6 | United States, The Netherlands, Germany | Series B, Series C, Series A | Health Care, Biotechnology, Medical | $9.5M–$135M |
|
Sunstone Life Science Ventures
VC Fund
|
6 | Denmark, Sweden, Switzerland | Series A, Series B | Biotechnology, Health Care, Medical | $5.5M–$52M |
|
Oskare Capital
VC Fund
|
6 | Italy, Denmark, United Kingdom | Seed, Series A, Pre-Seed | Health Care, Biotechnology, Medical | $1.2M–$5.9M |
|
Nordic Foodtech VC
VC Fund
|
6 | Finland, Denmark, Sweden | Seed, Pre-Seed, Series A | Biotechnology, Food and Beverage, Life Science | $610k–$18M |
|
2xN
VC Fund
|
5 | Denmark, United States, Finland | Seed, Series A, Series B | Software, Information Technology, Quantum Computing | $1.9M–$63M |
|
West Hill Capital
VC Fund
|
5 | United Kingdom, Denmark, Germany | Series A, Seed | Software, Health Care, Financial Services | $2M–$15M |
|
RA Capital Management
VC Fund
|
5 | United States, United Kingdom, Canada | Series B, Series C, Post-IPO Equity | Biotechnology, Health Care, Therapeutics | $27M–$240M |
|
The Footprint Firm
VC Fund
|
5 | Denmark, Spain, Norway | Seed, Pre-Seed, Series A | Software, Renewable Energy, Energy Management | $863k–$18M |
|
HealthCap
VC Fund
|
4 | United States, Sweden, France | Series B, Series A | Biotechnology, Health Care, Medical | $5.7M–$92M |
|
DSM Venturing
VC Fund
|
4 | United States, Canada, Israel | Series A, Series B | Health Care, Biotechnology, Manufacturing | $3.5M–$32M |
|
Per Falholt
Angel
|
4 | Denmark | Pre-Seed, Series A, Seed | Biotechnology, Robotics, Biopharma | $5.9M–$20M |
|
ACME Capital
VC Fund
|
4 | United States, Denmark, Canada | Seed, Series A, Series B | Software, Health Care, Mobile | $1.6M–$70M |
|
EIR Ventures
VC Fund
|
4 | Denmark, Sweden, United States | Series A, Seed | Biotechnology, Health Care, Therapeutics | $20M–$73M |
|
Ysios Capital
VC Fund
|
4 | Spain, United States, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $3.8M–$135M |
|
Atlantic
VC Fund
|
4 | Germany, Switzerland, United States | Seed, Pre-Seed, Series A | Software, Health Care, Artificial Intelligence | $850k–$30M |
|
VF Venture
VC Fund
|
4 | Denmark, United Kingdom, Iceland | Seed, Series A | Software, SaaS, Biotechnology | $1.2M–$22M |
|
PINC
VC Fund
|
4 | Sweden, Denmark, United Kingdom | Seed, Pre-Seed, Series A | Biotechnology, Food and Beverage, Agriculture | $89k–$7.2M |
|
Lundbeckfonden Ventures
VC Fund
|
3 | United States, Denmark, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $10M–$95M |
|
NOON Ventures
VC Fund
|
3 | Denmark | Seed, Series A | Biotechnology, AgTech, Farming | $4.3M–$8.8M |
|
Omega Funds
VC Fund
|
3 | United States, Switzerland, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $14M–$208M |
|
Blue Horizon Corporation
VC Fund
|
3 | United States, United Kingdom, Germany | Seed, Series A, Pre-Seed | Food and Beverage, Food Processing, Biotechnology | $450k–$40M |
|
Unconventional Ventures
VC Fund
|
3 | Sweden, Denmark, United Kingdom | Seed, Pre-Seed, Series A | Health Care, Software, Wellness | $1M–$18M |
|
Dawn Biopharma
VC Fund
|
3 | United States, Denmark, France | Series A, Seed, Series B | Biotechnology, Health Care, Therapeutics | $15M–$165M |
|
Sofinnova Partners
VC Fund
|
3 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $6.6M–$109M |
|
Karolinska
VC Fund
|
3 | Sweden, Denmark, United States | Seed, Series A | Biotechnology, Health Care, Pharmaceutical | $1.3M–$73M |
|
Innovation Fund Denmark
VC Fund
|
3 | Denmark, United States | Grant, Pre-Seed, Seed | Software, Biotechnology, SaaS | $35k–$1.6M |
|
HTGF (High-Tech Gruenderfonds)
VC Fund
|
3 | Germany, Switzerland, United States | Seed, Series A | Software, Biotechnology, Information Technology | $909k–$39M |
|
Ugly Duckling Ventures
VC Fund
|
3 | Denmark, Sweden, Finland | Seed, Pre-Seed, Venture - Series Unknown | Software, Information Technology, Artificial Intelligence | $876k–$7.5M |
|
Nicholas Francis
Angel
|
3 | Denmark, United States | Seed, Series A | SaaS, Robotics, Software | $983k–$8.1M |
|
Bioqube Ventures
VC Fund
|
3 | United States, France, Norway | Seed, Series A, Series B | Biotechnology, Therapeutics, Life Science | $4M–$108M |
|
Thia Ventures
VC Fund
|
3 | United States, France, Denmark | Series A, Seed, Pre-Seed | Biotechnology, Health Care, Manufacturing | $3.4M–$48M |
|
FundersClub
VC Fund
|
2 | United States, Canada, India | Seed, Series A, Pre-Seed | Software, Artificial Intelligence, SaaS | $450k–$23M |
|
SR One
VC Fund
|
2 | United States, United Kingdom, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $3.7M–$175M |
|
Wellcome Trust
VC Fund
|
2 | United States, United Kingdom, France | Grant, Series C | Biotechnology, Health Care, Medical | $1.6M–$127M |
|
Steen Riisgaard
Angel
|
2 | Denmark | Pre-Seed | Life Science, Therapeutics, Biotechnology | |
|
M Ventures
VC Fund
|
2 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
Balderton Capital
VC Fund
|
2 | United Kingdom, United States, Germany | Series A, Series B, Series C | Software, FinTech, Financial Services | |
|
SOSV
VC Fund
|
2 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
+ND Capital
VC Fund
|
2 | United States, Switzerland, Denmark | Series B, Series C, Series A | Biotechnology, Health Care, Medical | |
|
byFounders
VC Fund
|
2 | Denmark, United States, Sweden | Seed, Pre-Seed, Series A | Software, Artificial Intelligence, Health Care | $800k–$65M |
|
Nordic Alpha Partners
VC Fund
|
2 | Denmark, Germany, Sweden | Seed, Series A | Energy, Energy Storage, Manufacturing | $3M–$15M |
|
Verve Ventures
VC Fund
|
2 | Switzerland, Germany, France | Series A, Seed, Series B | Health Care, Software, Biotechnology | $1.4M–$45M |
|
Seventure Partners
VC Fund
|
2 | France, United States, Germany | Series A, Series B | Biotechnology, Health Care, Software | $3.3M–$63M |
|
Newtree Impact
VC Fund
|
2 | Denmark | Seed | Biotechnology | |
| Access all 376 investors in Denmark Biotech startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 370
- Round size: Series A $9.9M–$133M; Series B $12M–$135M; Series C $30M–$118M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $165M in 2018
Portfolio highlights
- Tarveda Therapeutics — Developing Pentarins to make a difference in the treatment of patients with solid tumor malignancies
- Tarsa Therapeutics — Tarsa Therapeutics is developing an oral formulation of calcitonin, a peptide hormone for the treatment of osteoporosis that slows the rate of bone destruction.
- Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Convertible Note, Pre-Seed, Seed
- Geography: Denmark, Germany, Switzerland
Investor stats
- Total investments: 92
- Round size: Seed $532k–$1.6M; Pre-Seed $516k–$5.2M; Convertible Note $495k–$1.6M
- Lead/follow: 92% lead, 8% follow
Portfolio highlights
- Visibuilt — Visibuilt develops sustainable, bio-based asphalt binders made from mycelium. Replace fossil bitumen with visiBIT.
- Loma Therapeutics — Loma Therapeutics is developing targeted immunotherapy for the effective and safe treatment of HPV infection, dysplasia, and cancer patients.
- metaLead Therapeutics — metaLead Therapeutics is to develop this peptide as a next-generation Pb poisoning treatment.
Denmark's Export and Investment Fund (EIFO) serves as a single point of contact for Danish firms seeking risk-tolerant government finance. We aspire to help successful enterprises that can expand the Danish economy and green the world on a daily basis, guided by professionalism and an international perspective.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 136
- Round size: Seed $457k–$11M; Series A $5.9M–$43M
- Lead/follow: 36% lead, 64% follow
Portfolio highlights
- EvodiaBio — EvodiaBio is a bio-industrial firm that creates natural, sustainable scents for the food and beverage industries. Founded in 2021 and is based in Copenhagen, Capital Region.
- MATR Foods — MATR Foods is a food-tech startup that provides fungi-based food ingredients offering dishes produced from fungi like mushrooms, vegetables, and fruits.
- VentriJect — VentriJect is a is a research facility that incorporates measuring cardiorespiratory fitness into everyone's checkup. They estimate respiratory fitness, which is a simple process. As a health indicator, people can increase their cardiorespiratory fitness. They have compiled a list of some of the other pertinent articles that relate to thesignificance of VO2-max measurement.
Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.
Show more...Investment focus
- Industry: Software, Information Technology, SaaS
- Stage:Seed, Pre-Seed
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 209
- Round size: Seed $830k–$5.3M; Pre-Seed $384k–$1.2M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- Deskwolf — Desk Wolf helps SMEs to take advantage of Facebook to generate more sales, more customers, and promote their business in an efficient manner.
- Advalight — Advalight is a young, dynamic company dedicated to providing high-quality laser equipment for dermatological treatments. The company has patented an innovative technology for use in the removal of vascular lesions, acne treatment, skin rejuvenation and many other skin-enhancing procedures. The ground-breaking product was launched the summer 2014.Advalight is based on five years of scientific work in the Physics Department at the Technical University of Denmark. The founders include two PhDs and it is their research that forms the basis of Advalight. The company's main focus is on research and development and with the right external partners we believe that the market for dermatological lasers will be transformed. Advalight is therefore seeking collaboration with external partners with established distribution and sales channels.
- CrossEyes — CrossEyes is a Danish optician chain founded in Aarhus in 2010. Our frames are only available in CrossEyes stores and the designs are inspired by current trends and the Scandinavian simplicity.We believe that glasses are not just a tool to see better: They are a fashion accessory and reflects personality and individual style. We get newcollections 10-12 times annually to make sure there’s always news on the shelves – from the everyday classic Original frame to the colorful and trendy Limited.Our vision is to change the eyewear and optical world. We offer a unique customer experience through stunning eyewear, honest pricing, and legendary service. We do this by putting the customer first in every aspect of our business, as we see our customers as ambassadors for our glasses. We strive to give them the best service possible – every time.
Seed Capital invests in Danish tech businesses with global ambitions. We are focused on "late seed"-stage companies, typically investing 1-3 MEUR in rounds of 1-6 MEUR. Proud backers of Trustpilot, Vivino, Lunar, Templafy, Dixa, Forecast, and many other great companies.
Show more...Investment focus
- Industry: Software, Health Care, SaaS
- Stage:Seed, Series A
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 191
- Round size: Seed $549k–$5.2M; Series A $3.8M–$17M
- Lead/follow: 29% lead, 71% follow
- Last fund: May invest from a new fund soon — raised $73M in 2021
Portfolio highlights
- eloomi — eloomi is an LMS platform for your workplace to train, retain & engage employees. Explore impactful learning & development today.
- Flatpay — Flatpay's fair, flat-rate pricing simplifies payments & cuts costs. Benefit from our comprehensive solution & superior customer service. Join us now!
- Asante Solutions — Asante Solutions was founded more than a decade ago in Denmark. While there, they developed close relationships with a select group of European-based venture capitalists. Backed with venture seed money, they began early stage development of an insulin delivery device that would ultimately become their first product - the Pearl Insulin Pump.
PSV cares about a conscious future. As a venture house, our mission is to clear the path for founders who build companies that matter. Our hybrid setup, comprising PSV Foundry, PSV Lab, and two unique venture funds, PSV Tech and PSV Hafnium, sets us free from adhering to a singular method. Rather we rethink existing ways and models to maximise our impact beyond any individual firm or investment. Together, we can punch above our weight.
Show more...Investment focus
- Industry: Software, Information Technology, SaaS
- Stage:Seed, Pre-Seed
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 149
- Round size: Seed $500k–$4.6M; Pre-Seed $353k–$2.5M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — raised $42M in 2020
Portfolio highlights
- Woba — Woba is a SaaS aiming to support a stress-free work environment and minimise sick leave.
- Jabbr — Jabbr allows to capture boxing matches with a virtual video production.Its goal is to make video production and advanced performance analytics in combat sports available to anyone with a smartphone.
- eloomi — eloomi is an LMS platform for your workplace to train, retain & engage employees. Explore impactful learning & development today.
Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series C, Series A
- Geography: United States, The Netherlands, Germany
Investor stats
- Total investments: 131
- Round size: Series A $9.5M–$63M; Series B $15M–$135M; Series C $21M–$75M
- Lead/follow: 38% lead, 62% follow
- Last fund: Likely still investing — raised $786M in 2023
Portfolio highlights
- Big Health — Our mission is to help millions back to good mental health. Our digital therapeutics are safe and effective non-drug alternatives for mental health.
- GT Medical Technologies — GammaTile is an FDA-cleared, bioabsorbable collagen implant embedded with radiation seeds, designed for patients with operable brain tumors.
- Endovascular Engineering — Endovascular Engineering is a medical technology company focused on developing and deploying advanced clot removal solutions for the treatment of venous thromboembolism. It specializes in thrombectomy technologies designed to improve clinical outcomes and procedural efficiency in minimally invasive vascular interventions. The company’s flagshipinnovation is the Hēlo™ Thrombectomy System, a catheter-based device that uses a combination of mechanical agitation and physician-controlled aspiration to remove blood clots. Its technology emphasizes features such as a self-expanding funnel design and dual-action functionality to enhance clot engagement and navigation through complex anatomies. Endovascular Engineering primarily serves healthcare providers, including interventional cardiologists and radiologists, supporting the treatment of conditions such as pulmonary embolism and deep vein thrombosis.
Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B
- Geography: Denmark, Sweden, Switzerland
Investor stats
- Total investments: 61
- Round size: Series A $5.5M–$44M; Series B $9.6M–$52M
- Lead/follow: 16% lead, 84% follow
- Last fund: May invest from a new fund soon — raised $94M in 2019
Portfolio highlights
- Step Pharma — Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe.
- Resalis Therapeutics — Resalis Therapeutics sviluppa un farmaco in grado di inibire un micro-RNA per il trattamento di alcune malattie metaboliche
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
Oskare Capital is a venture capital firm.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A, Pre-Seed
- Geography: Italy, Denmark, United Kingdom
Investor stats
- Total investments: 9
- Round size: Seed $1.2M–$3.4M; Series A $4.7M–$5.9M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- Leva Clinic — Leva Clinic offers health care services for people with chronic pain. Their medical services include back pain, cancer pain, endometriosis, facial pain, fibromyalgia, joint pain, knee pain, multiple sclerosis, sciatica, and so on.
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
- Herbolea Biotech — Unique bio-processing technologies NATURAL, SOLVENT-LESS Botanical extraction Learn more
We are investing in #FutureFood. Nordic FoodTech VC is the first fund in the Nordics investing explicitly in the future of food
Show more...Investment focus
- Industry: Biotechnology, Food and Beverage, Life Science
- Stage:Seed, Pre-Seed, Series A
- Geography: Finland, Denmark, Sweden
Investor stats
- Total investments: 30
- Round size: Seed $610k–$5.3M; Pre-Seed $880k–$1.9M; Series A $6.8M–$18M
- Lead/follow: 57% lead, 43% follow
- Last fund: Likely still investing — raised $49M in 2021
Portfolio highlights
- Fiberdom — Fiberdom develops sustainable materials from wood fibers, focusing on plastic-free solutions. The company offers a range of compostable cutlery designed for food service and take-away applications. These products are fully recyclable and comply with European regulations, making them suitable for environmentally conscious consumers. Fiberdomemphasizes innovation in transforming wood fibers into high-performance materials, contributing to sustainability efforts in various industries. The commitment to creating eco-friendly alternatives positions Fiberdom as a key player in the materials innovation sector.
- Enifer — Enifer Bio is an expert at squeezing every last drop of value from biorefining operations. The solution is built on decades of Finnish expertise to allow the production of valuable protein-rich feed from streams previously considered worthless. The company has developed a new, sustainable production process for high-quality fish feed raw material.The company's method enables the efficient production of a single cell protein from fish by-products as a raw material for fish feed. The protein can replace soy, which is commonly used in fish feed and whose cultivation poses ecological challenges, such as deforestation in South America.
- MÖ Foods — MÖ Kaurajogu is domestic, completely herbal and above all delicious. All our products are manufactured in Central Ostrobothnia, Lohtaja.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!2xN operates as a venture capital firm.
Show more...Investment focus
- Industry: Software, Information Technology, Quantum Computing
- Stage:Seed, Series A, Series B
- Geography: Denmark, United States, Finland
Investor stats
- Total investments: 35
- Round size: Seed $1.9M–$6.9M; Series A $6.4M–$63M; Series B $15M–$50M
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- Kvantify — Quantum computing will revolutionize many aspects of computing. We can help your business harness the full potential of Quantum Computing and High-Performance Computing today.
- QSimulate — QSimulate is a simulation platform that solves pressing problems for the chemical and pharmaceutical industries. It aims to deliver best-time-to-solution algorithms to chemical and pharmaceutical industries to accelerate their computational R&D. It is headquartered in Cambridge, Massachusetts.
- Sparrow Quantum — Sparrow Quantum, a global leader in quantum photonic chip technology. Explore innovative solutions driving advancements in quantum computing, communication, and beyond. Stay ahead with cutting-edge technologies shaping the future.
West Hill Corporate Finance is a leading private equity venture capital firm providing EIS qualifying high-growth investments to private individuals.
Show more...Investment focus
- Industry: Software, Health Care, Financial Services
- Stage:Series A, Seed
- Geography: United Kingdom, Denmark, Germany
Investor stats
- Total investments: 60
- Round size: Seed $2.6M–$6M; Series A $2M–$15M
- Lead/follow: 83% lead, 17% follow
Portfolio highlights
- Silicon MicroGravity — Silicon Microgravity Limited is a spin-out from Cambridge University. The underpinning sensor technology was developed through a collaboration with BP plc and provides a breakthrough in the management of oil and gas reservoirs. The technology has been developed in Cambridge University’s Nanoscience Centre primarily funded by BP and Innovate UK.
- ATLANT 3D — Micro and nanodevices are built and tested within days instead of months or years.
- Formalize — Formalize delivers a cloud-based compliance operations platform designed for governance, risk, and control workflows, enabling businesses to automate processes around frameworks such as NIS2, DORA, ISO 27001, and GDPR. The platform lets users centralize risk and incident tracking, manage third-party audits and controls, and build customizeddashboards and workflows across compliance, supplier management, and governance.
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series C, Post-IPO Equity
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 518
- Round size: Series B $27M–$152M; Series C $44M–$183M; Post-IPO Equity $35M–$240M
- Lead/follow: 36% lead, 64% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- EvodiaBio — EvodiaBio is a bio-industrial firm that creates natural, sustainable scents for the food and beverage industries. Founded in 2021 and is based in Copenhagen, Capital Region.
- Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
- Kinaset Therapeutics — Kinaset Therapeutics is a therapeutics company that focuses on the advancement of novel drugs in areas of unmet medical needs. The company was founded in 2020 and is headquartered in Medfield, Massachusetts.
The Footprint Firm is an advisory and investment company with a sole focus on sustainability.
Show more...Investment focus
- Industry: Software, Renewable Energy, Energy Management
- Stage:Seed, Pre-Seed, Series A
- Geography: Denmark, Spain, Norway
Investor stats
- Total investments: 25
- Round size: Seed $2.2M–$5.4M; Pre-Seed $863k–$4M; Series A $4.7M–$18M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Vaja — Vaja is on a mission to accelerate the transition to a net-zero world via disruptive innovations for solar farms.
- Reel Energy — Reel empowers all companies to procure renewable electricity that makes a real difference for the climate.
- Kvasir Technologies — Imagine a world without fossil fuelsThis is where we come in! We have invented a solution that makes this possible already in 2050.
HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: United States, Sweden, France
Investor stats
- Total investments: 133
- Round size: Series A $5.7M–$85M; Series B $12M–$92M
- Lead/follow: 24% lead, 76% follow
- Last fund: May invest from a new fund soon — raised $209M in 2019
Portfolio highlights
- Neobiomics — Neobiomics is a Swedish life-science company that develops nutritional products for preterm infants and neonatal care. Its best-known products include ProPrems® and NeoMega36®.
- CurifyLabs — CurifyLabs enables 3D printed personalized medicines in pharmacies and hospitals. Always close to the patient.
- Ultragenyx Pharmaceutical — Ultragenyx is focused on developing first-ever approved treatments for rare and ultrarare diseases and moving the rare disease community forward.
Innovators in nutrition, health, and beauty. Together, we bring progress to life by combining the essential, the desirable, and the sustainable.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Manufacturing
- Stage:Series A, Series B
- Geography: United States, Canada, Israel
Investor stats
- Total investments: 94
- Round size: Series A $3.5M–$32M; Series B $5.6M–$30M
- Lead/follow: 51% lead, 49% follow
- Last fund: May invest from a new fund soon — last raise in 2012
Portfolio highlights
- Athian — Funding livestock sustainability via a connected carbon marketplace.
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
- Meala Foodtech — Revolutionary texturized plant proteins that replace eggs and hydrocolloids. Clean-label, allergen-free solutions for baking, savory foods, and dressings.
A passion and vision for chemistry and biotechnology led Per (born 1958) to Novo A/S, where he started his career as a research chemist. He subsequently held several managerial positions developing products for the detergent industry and rose to Director for Application Technology in the company’s new enzyme development division in 1995.Hemoved to Raleigh, N.C., to head the company’s U.S. application technology unit in 1997, returning to Denmark three years later as Corporate Vice President of the Enzyme Development and Application division. In April 2000, Per merged the Research and Development division into the newly formed Enzyme Business R&D.Per assumed his current position following Novozymes’ demerger from Novo Nordisk in 2000. As chief science officer, he has helped Novozymes develop a unique industrial biotechnology platform which delivers solutions to meet customer needs and support growth.Per holds a M.Sc. in Chemical Engineering from Technical University of Denmark (DTU). Committed to promoting education and research within the sciences, he was appointed Honorary Professor at DTU’s Institute for Systems Biology in 2010 and became Chairman of the Board in 2013. He is also Chairman of the Young Scientists association in Denmark.Per’s current external positions also include Chairman, DTU, board member of DHI Group, board member of ARTs Biologics A/S, and member of the Danish Council for Research Policy.
Show more...Investment focus
- Industry: Biotechnology, Robotics, Biopharma
- Stage:Pre-Seed, Series A, Seed
- Geography: Denmark
Investor stats
- Total investments: 5
- Round size: Series A $5.9M–$20M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Visibuilt — Visibuilt develops sustainable, bio-based asphalt binders made from mycelium. Replace fossil bitumen with visiBIT.
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
- Synamics Therapeutics — Synamics Therapeutics uses AI and predictive modeling for precision oncology and improved drug discovery. Our adaptive medicine approach helps prolong drug effectiveness and improves outcomes for patients with intractable cancers. Learn more about Synamics Therapeutics and how we leverage AI for personalized, adaptive cancer therapies.
ACME Capital is a venture capital and private equity firm that invests in breakthrough technologies that fuel platform shifts and disruptive business models that capitalize on new platforms. Its purpose is to support those founders who choose to take their capital. The firm was founded in 2018 and headquartered in San Francisco, California.
Show more...Investment focus
- Industry: Software, Health Care, Mobile
- Stage:Seed, Series A, Series B
- Geography: United States, Denmark, Canada
Investor stats
- Total investments: 175
- Round size: Seed $1.6M–$10M; Series A $4.4M–$30M; Series B $15M–$70M
- Lead/follow: 22% lead, 78% follow
- Last fund: Likely still investing — raised $300M in 2022
Portfolio highlights
- Plot — We power the best creative teams to help streamline creative development and cross-collaborate in one source of truth.
- NexGenT — Launch Your IT Career in Networking or Cyber Security Online With Our Military Grade Inspired Next Generation Training Programs. Go From Zero To Engineer within 6 months! Zero Up Front Tuition Options Available!
- Doctor On Demand — 24/7 Online doctors are available. Same week mental health appointments for therapy and psychiatry.
EIR Ventures is a new Life Science Venture Group in the Nordics.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Seed
- Geography: Denmark, Sweden, United States
Investor stats
- Total investments: 13
- Round size: Series A $20M–$73M
- Lead/follow: 54% lead, 46% follow
- Last fund: Likely still investing — raised $143M in 2021
Portfolio highlights
- ArgusEye — ArgusEye is a biotechnology company that provides sensor solutions for real-time detection of biological systems and processes. ArgusEye's patented sensor technology is the result of extensive academic research and is based on nanoplasmonic sensing with fiber optics. By adding customized receptors, ArgusEye can offer flexible and sensitivesensing systems for a variety of targets.
- Moleculent — Moleculent is adding a functional layer of biology to pave the way for unparalleled advancements in biological research.
- Hoba Therapeutics — Hoba Therapeutics is developing a new therapeutic protein for the treatment of neuropathic pain.
Leading #lifesciences #venturecapital firm financing highly #innovative #biotechnology companies #worlwide.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: Spain, United States, Switzerland
Investor stats
- Total investments: 81
- Round size: Series A $3.8M–$62M; Series B $20M–$135M; Series C $27M–$80M
- Lead/follow: 30% lead, 70% follow
Portfolio highlights
- AM Pharma — AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derivedpeptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
- Inbiomotion — Inbiomotion is focused on the development and commercialization of a biomarker that predicts metastasis to improve patients' quality of life by personalizing the adjuvant treatment of early stage breast cancer. Founded in 2010 by Dr. Roger Gomis, it is a spin-off of IRB Barcelona and ICREA research institutions.Inbiomotion's uniquediagnostic assay is based on a highly selective single gene biomarker. Data generated thus far suggests such biomarker can identify early stage breast cancer patients that will benefit from bisphosphonate adjuvant treatment improving their overall and invasive disease free survival. It can further predict at an early stage a patient's risk of metastases relapse from primary tumors. The selectivity of the lead biomarker has the potential to advance the clinical standard of care using personalized medicine.
- Splice Bio — Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Atlantic Labs supports and invests in mission-driven founders working on transformative technology ventures. <br><br>We partner with founders early, providing the capital, tools and network necessary to growing their companies and accompanying them on their entrepreneurial journey. We are currently active in areas including Digital Health, Future of Work, Machine Learning, Decentralized Networks, Mobility and Industrial Applications.
Show more...Investment focus
- Industry: Software, Health Care, Artificial Intelligence
- Stage:Seed, Pre-Seed, Series A
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 234
- Round size: Seed $1.3M–$9.4M; Pre-Seed $850k–$3.5M; Series A $5.3M–$30M
- Lead/follow: 44% lead, 56% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- bonify — Bonify, a Berlin based FinTech-Start-up, enables customers to benefit from their credit scoring and financial data. The company gives customers free and easy access to their credit score and let them upload additional relevant data. Then, it offers tools and personalized recommendations to help optimize the customer’s financial situation.Foundedin 2015 by key executives of McKinsey and Zalando, bonify has received significant funding from internationally leading VCs and successful entrepreneurs.
- Stenon — Stenon is a laboratory independent real-time soil analyst that offers solutions for agriculture.
- 42matters — 42matters offers a full suite of mobile and connected TV app intelligence solutions, including APIs, file dumps, and visual, web-based platforms.
Vaekstfonden makes equity investments in Danish companies with a track record as well as in young entrepreneurial, innovative enterprises with an ambition for global growth.
Show more...Investment focus
- Industry: Software, SaaS, Biotechnology
- Stage:Seed, Series A
- Geography: Denmark, United Kingdom, Iceland
Investor stats
- Total investments: 30
- Round size: Seed $1.2M–$9.1M; Series A $3.5M–$22M
- Lead/follow: 30% lead, 70% follow
Portfolio highlights
- Rokoko — Rokoko | Affordable high-end motion capture and animation tools for body, hand, and face capture + software with native integrations for all major animation software and game engines
- Kollektiv — Unleash your best self with tailored training plans, learning and support for running, swimming and cycling - from world-class-coaches and ex-athletes.
- Performativ — Performativ develops modern solutions for the asset and wealth management industry. Our clients span from small investment advisors to enterprise banks.
PINC was launched as Paulig Incubator in 2018 to help Paulig stay in the forefront of relevant innovations, as well as to contribute to a tastier, healthier and more sustainable planet. Today, our ambition is the same, but we have developed into a corporate venture arm. We aim for strategic, financial, and societal impact in our investments,fostering a sustainable food system for tomorrow. We are investing across the agrifood value chain in three primary impact themes: Improve planetary health and diet within the current food system: This includes innovations in agriculture and food security, such as advanced crop breeding or green fertilizers, innovative ingredients and next generation healthy foods, as well as solutions for tracking and improving climate and nature. Novel technologies to feed 10 BN people by 2050: Technologies needed to sustainably produce enough food for our growing population. This includes food production without land use change, such as precision fermentation and cell-culture. A circular system for food & materials: Regardless of whether we grow our food in soil or in bioreactors, the system needs to be circular. Some examples are upcycled ingredients, food from unused sources, new coating and packaging solutions, as well as technologies to prevent or make better use of side streams. We are looking for entrepreneurs in an attractive market space with an intrinsic drive to find a solution to the problem they are addressing, a clear and scalable plan for success, a reliable team and partners whom we can trust and work closely with.
Show more...Investment focus
- Industry: Biotechnology, Food and Beverage, Agriculture
- Stage:Seed, Pre-Seed, Series A
- Geography: Sweden, Denmark, United Kingdom
Investor stats
- Total investments: 23
- Round size: Seed $907k–$7M; Pre-Seed $89k–$2.8M; Series A $4.1M–$7.2M
- Lead/follow: 26% lead, 74% follow
Portfolio highlights
- Amatera — Amatera is a biotechnology research company that leverages the latest techniques in biotechnology, to create coffee varieties. Amatera urges to make coffee varieties more sustainable and climate resistant to fill that massive demand. Founded by Omar Dekkiche and Lucie Kriegshauser in 2022 and is located in Paris, France.
- Mycoverse — Mycoverse is a agri-biotech startup specializes in developing fungal-based biological crop protection solutions to replace chemical pesticides, targeting row crops with an initial focus on potato late blight.
- Rainbow Crops — Rainbow Crops is a next-generation Agtech company developing climate-resilient, high-performing crop varieties.
Lundbeckfond Ventures is an evergreen life science venture fund established in the autumn of 2009 and wholly owned by the Lundbeck Foundation. The structure as an evergreen fund allows flexibility in the investment approach and the possibility, when appropriate, to take a long-term perspective in the investments. On an annual basis, LundbeckfondVentures invests up to € 50 million.Lundbeckfond Ventures is a financially driven venture fund generating returns to support the group's activities and operating independently from the Lundbeck Foundation’s controlling ownerships in H. Lundbeck A/S, ALK-Abelló and Falck.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 70
- Round size: Series A $10M–$50M; Series B $20M–$95M; Series C $16M–$53M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Kvantify — Quantum computing will revolutionize many aspects of computing. We can help your business harness the full potential of Quantum Computing and High-Performance Computing today.
- SNIPR Biome — We are the CRISPR Microbiome Company; Our mission is to develop CRISPR-based medicines that give hope for effective and safe treatment of difficult-to-treat diseases in the future.
- Women in Life Science Denmark — WiLD is a networking platform for women in senior positions in business and academia that is motivating and focused on science.
Noon Ventures is a Copenhagen-based, early-stage venture investor established in 2020. We invest in proven transformative technologies with the potential to impact environmental or climate challenges.
Show more...Investment focus
- Industry: Biotechnology, AgTech, Farming
- Stage:Seed, Series A
- Geography: Denmark
Investor stats
- Total investments: 6
- Round size: Seed $4.3M–$8.8M
- Lead/follow: 83% lead, 17% follow
Portfolio highlights
- Agrobiomics — Agrobiomics is a danish Agritech start-up, harnessing the power of soil bacteria and their metabolites as new biostimulants to help crops cope with abiotic stress such as drought.
- Enduro Genetics — Bioproduction can be difficult to scale to large cultivation volumes while keeping titers high. By applying game-changing synthetic biology technology, Enduro Genetics empowers our partner companies to maximize performance of all cells cultivated from their production strains.
- Lotus Microsystems — Lotus Microsystems offers miniaturized highly integrated point of load power converters. The devices are engineered for portable electronics manufacturers ready for usage whenever tiny power supply units are needed. Our devices offer up to 72% reduction in footprint compared to existing solutions with higher efficiency and reliability. Our plug andplay solutions enable our customers to innovate their electronics without worrying about power supply units.
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 161
- Round size: Series A $16M–$187M; Series B $37M–$162M; Series C $14M–$208M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Attenua — 100% satisfaction guaranteed. Hassle-free shopping. We help you find the right domain name.
- Andrew Alliance — OneLab is laboratory software to design and execute liquid handling protocols. Pipette+ for manual liquid handling pipetting and Andrew+ the pipetting robot
- Chord Therapeutics — Chord Therapeutics is a clinical stage pharmaceutical company developing drugs for patients with rare, life-threatening and severely disabling diseases. We are advancing our lead drug candidate CRD1 under orphan drug designation for the treatment of neuromyelitis optica spectrum disorders (NMOSD) and myasthenia gravis (MG).
Blue Horizon is accelerating the transition to a sustainable food system that delivers outstanding returns for the planet and people.
Show more...Investment focus
- Industry: Food and Beverage, Food Processing, Biotechnology
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 98
- Round size: Seed $2M–$12M; Pre-Seed $450k–$6.3M; Series A $2M–$40M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $187M in 2021
Portfolio highlights
- WOW EARN — Discover WOW EARN, the all-in-one Web3 app with crypto mining, multi-chain wallet, staking NFTs, and marketplace dApps. Join the global Web3 community today.
- EV Biotech — We design and optimise your precision fermentation strains and processes, tailored to your success.
- foodforecast — AI supported solution to reduce food waste.
Unconventional Ventures invests in startups in the pre-seed and seed stage led by diverse founders identifying as women, people of color, immigrants and/or LGBTQ+, building scalable impact tech companies in the Nordics and beyond.
Show more...Investment focus
- Industry: Health Care, Software, Wellness
- Stage:Seed, Pre-Seed, Series A
- Geography: Sweden, Denmark, United Kingdom
Investor stats
- Total investments: 19
- Round size: Seed $1M–$5.2M; Pre-Seed $1.5M–$2.8M; Series A $4.7M–$18M
- Lead/follow: 42% lead, 58% follow
Portfolio highlights
- Visibuilt — Visibuilt develops sustainable, bio-based asphalt binders made from mycelium. Replace fossil bitumen with visiBIT.
- AIRMO — AIRMO is supporting the direct emitters, decision makers and financial institutions to efficiently transition to Net-0 by monitoring their direct emissions from space. With our roots in innovation and a commitment to environmental responsibility, we aim to revolutionize GHG monitoring through advanced satellite technology, proprietary LiDARinstrument and data analytics. We exist to monitor and manage humanity's impact on Earth.
- Digiclean Solutions — AI-powered process chemical control that gives you lower costs, higher efficiency, and a radically smaller footprint.
Dawn Biopharma is a global investment firm of KKR.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Seed, Series B
- Geography: United States, Denmark, France
Investor stats
- Total investments: 14
- Round size: Seed $15M–$32M; Series A $17M–$165M; Series B $115M–$135M
- Lead/follow: 21% lead, 79% follow
Portfolio highlights
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- Vedana Therapeutics — Vedana Therapeutics is a Seattle biotechnology company developing next-generation antibody therapies for migraine prevention.
- Expedition Therapeutics — Redefining Care. Advancing COPD and Other Respiratory Therapies. Expedition Therapeutics is developing novel treatments for inflammatory and respiratory diseases with the potential to fundamentally transform patient care worldwide. ABOUT US At Expedition Therapeutics, we believe that disease-controlling treatments that address fundamental disease mechanisms should be the new standard for chronic obstructive pulmonary disease (COPD). Our
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 329
- Round size: Series A $6.6M–$70M; Series B $10M–$109M; Series C $12M–$100M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- Odoo — From ERP to CRM, eCommerce and CMS. Download Odoo or use it in the cloud. Grow Your Business.
- Biosyntia — Biosyntia is a biotech startup within synthetic biology and metabolic engineering. We develop biocatalysts at an unprecedented speed and efficiency by employing our patent pending high-throughput screening technology.By developing tailored processes based on biocatalysis, Biosyntia enables production of complex chemical compounds byfermentation. Biocatalysis may substantially reduce both production costs and environmental impact compared to other processes such as chemical synthesis. We partner with manufacturers of fine chemical compounds (flavors, fragrances, APIs, pigments, additives, intermediates, and more) in order to establish more sustainable manufacturing processes for a greener tomorrow.Biosyntia is located at the Novo Nordisk Foundation (NNF) Center for Biosustainability in Hørsholm, 25 kilometers north of Copenhagen.
- Comet Biorefining — Comet Biorefining is a leading provider of sustainable high-quality cost-competitive cellulosic glucose technology for applications in renewable biofuels and biochemicals. The company’s proprietary technology allows for the conversion of wood, wheat straw, bagasse, corn stover and other agricultural waste materials into high purity cellulosicglucose syrup. These non-food sources offer lower cost and price stability when compared to food sugar sources such as corn or sugar cane. Demonstrated at 5 dry tons per day scale, Comet is focusing on commercial scale up and development of commercial partnerships with applications in renewables industries.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatestreturn on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.Karolinska Development has developed a well-structured selection process to identify the most commercially attractive medical innovations screened by KIAB. Pharmaceutical development is a high-risk enterprise. In most cases, development projects fail because of side effects or insufficient efficacy. Successful selection of innovations is fundamental to Karolinska Development’s business model, which makes the inflow of new projects crucial. One key to success lies in selecting those innovations that can be developed from scientific findings to products and have significant commercial potential. To date, over 1,300 projects have been screened by KIAB.The portfolio companies are often founded together with the innovators and are initially operated as virtual companies with few or no employees. During the first six to twelve months, the companies normally have minimal fixed costs and technological development is outsourced.The innovator, who is often employed at an academic institution, normally participates as a board member and scientific advisor. The CEO of a portfolio company cooperates closely with a representative of Karolinska Development, who in most cases is also a board member of the company. The companies are capitalized to reach their next milestone, usually within a period of six to eighteen months. Development projects are continuously monitored, and those that do not meet their stipulated targets are discontinued. In the first three to four years, a portfolio company’s operating expenses are often limited to a few million Swedish kronor per year, which cover the cost of external studies and the salary of the staff. In subsequent years, Karolinska Development and other investors play an important role recruiting key expertise to the companiesKarolinska Development intends to realize value by exiting portfolio companies or through out-licensing of projects. Such transactions (especially out-licensing) are often structured as single upfront payments followed by payments based on predetermined milestones and royalties on sales. Although Karolinska Development has a flexible exit strategy, pharmaceutical products are, for two reasons, preferably exited at Phase II. First a successful Phase II study indicates that the pharmaceutical has an effect on patients, which is an important value-enhancing factor when negotiating out-licensing or sales. Secondly, finalizing product development and undertaking Phase III clinical trials frequently requires very large patient populations. In many cases this requires much greater resources than those available at Karolinska Development but these can be found in established pharmaceutical companies. Several licensing deals were closed in 2011 involving projects with a similar focus and development phase to Karolinska Development's projects.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Seed, Series A
- Geography: Sweden, Denmark, United States
Investor stats
- Total investments: 32
- Round size: Series A $1.3M–$73M
- Lead/follow: 34% lead, 66% follow
Portfolio highlights
- BOOST Pharma — Boost Pharma: Developing a stem cell therapy for Osteogenesis Imperfecta.
- Modus Therapeutics — Modus Therapeutics is a Swedish drug development company developing sevuparin – a novel drug to treat people suffering from Sickle Cell Disease – a painful, inherited blood disorder affecting millions of people around the globe.
- Umecrine Cognition — Umecrine Cognition is a Swedish clinical-stage pharmaceutical company developing a novel class of drugs to treat neurological disorders of the brain.
Innovation Fund Denmark invests in the development of new knowledge and technology creating growth and employment in Denmark. The Fund focuses on societal challenges, strengthens research, and increases innovation commitment within private companies.The Fund provides risk capital that enables cutting-edge initiatives to achieve resultssubstantially impacting the Danish society. Innovation Fund Denmark is also responsible for the future societal partnerships, where companies, universities, and public authorities will work together on challenges facing the society today.
Show more...Investment focus
- Industry: Software, Biotechnology, SaaS
- Stage:Grant, Pre-Seed, Seed
- Geography: Denmark, United States
Investor stats
- Total investments: 96
- Round size: Seed $66k–$1.3M; Grant $35k–$1.2M; Pre-Seed $64k–$1.6M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Prezio — Access comprehensive electricity tariff data across Europe via one API
- PerPlant — PerPlant gives tractors the ability to see every plant. AI-powered cameras that cut input costs by 50% on average.
- SureShot — SureShot empowers you and your audience to become video co-creators. With our cutting-edge AI, capture, edit, and share electrifying videos that amplify the essence of every event.
High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Series A
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 610
- Round size: Seed $909k–$7M; Series A $3.5M–$39M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — raised $522M in 2022
Portfolio highlights
- CorTec — Reliable products for active implantable device development. We realize your next project with you and offer individual solutions that meet your specific requirements for Medical Devices, especially in neurotechnology.
- Coinlend — Coinlend - The Lending-Bot for Bitfinex & Liquid Genearate interest from your Bitcoin and Altcoin investments!
- CenterPoint - Connective Software Engineering — CenterPoint was founded in 2000 and is based in Villach, Austria with an additional office in Warsaw, Poland. CenterPoint - Connective Software Engineering develops and markets process control and fault detection and classification software solutions. The company offers cause effect analysis, metrology assessment, and close loop and run to runcontrol services. It's focus are the semiconductors, electronics, and steel and alloy industries.
At Ugly Duckling Ventures, we make capital, know-how, and real-world application available to Nordic ventures at the seed & pre-seed stage. We are operational by nature and want to get in the grind as we excel at getting early-stage ventures ready for scale.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Pre-Seed, Venture - Series Unknown
- Geography: Denmark, Sweden, Finland
Investor stats
- Total investments: 20
- Round size: Seed $876k–$5.5M; Pre-Seed $917k–$1.7M; Venture - Series Unknown $1.1M–$7.5M
- Lead/follow: 60% lead, 40% follow
Portfolio highlights
- Skyfora — Skyfora delivers sub-kilometer insights, nowcasts, and probabilistic forecasts so your teams can plan with confidence, no matter the weather.
- P-Secure — P-Secure is Europe's only automated platform for EU-compliant background checks. Screening employees, applicants and suppliers in minutes.
- Financial News Systems — Real-time News for Investment Professionals
Nicholas Francis is based out of Copenhagen, Hovedstaden, and is the Founder of Francis Family Funds. Nicholas previously worked at framebunker as a Co-Founder.
Show more...Investment focus
- Industry: SaaS, Robotics, Software
- Stage:Seed, Series A
- Geography: Denmark, United States
Investor stats
- Total investments: 4
- Round size: Seed $983k–$8.1M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Waterplan — Waterplan creates a water resilience planning platform for managing water availability in facilities. The company employs artificial intelligence to automatically collect operational data from businesses and combine it with local water satellite imagery to provide a real-time financial assessment of water risk and to offer modified mitigation andadaptation options.
- Reshape Biotech — Fully digital microbiology developed by Reshape Biotech
Bioqube Ventures is a specialist life sciences venture capital fund investing in European biotech companies developing innovative therapeutic assets and technologies. We put our venture creation experience at work to translate and de-risk scientific innovation, advancing our investment portfolio and maximising value for investors.Bioqube Venturesinvests through its independent fund “Bioqube Factory Fund I”: … an early stage venture capital fund – dedicated to advancing exciting science in vibrant European ecosystems to breakthrough therapies for patients.… a fit-for-purpose dual investment model – besides more classical investments in first investment rounds, we will have special attention for so called “Create” projects that require additional de-risking prior to creating new ventures. … a hands-on approach – the team is a mix of fund managers, sector experts and serial entrepreneurs that have a proven track record in successfully leading companies on their growth paths.Medtech, healthtech and diagnostics are not part of our current investment scope.
Show more...Investment focus
- Industry: Biotechnology, Therapeutics, Life Science
- Stage:Seed, Series A, Series B
- Geography: United States, France, Norway
Investor stats
- Total investments: 18
- Round size: Seed $5.7M–$24M; Series A $4M–$76M; Series B $23M–$108M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — last raise in 2020
Portfolio highlights
- Actithera — Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows.
- Spica Therapeutics — Spica Therapeutics is a pioneering biotech company dedicated to transforming macrophage biology into breakthrough therapies for patients across multiple therapeutic areas. Leveraging its proprietary functional macrophage fingerprinting technology, Spica identifies and selectively targets disease-relevant macrophage sub
- Primmune Therapeutics — Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability.
WE ARE AN EARLY-STAGE INVESTOR IN ONE OF THE MOST DYNAMIC AND ESSENTIAL FIELDS OF CURRENT HUMAN ENDEAVOR WE BRING ROBUST INVESTOR MUSCLE TO EARLY-STAGE VENTURES INVESTOR A specialized and focused investor Resources Powerful industry, substance and business resources Experience Wide networks and longstanding experience Team Yet, adaptability and speed of a lean, self-financed team
Show more...Investment focus
- Industry: Biotechnology, Health Care, Manufacturing
- Stage:Series A, Seed, Pre-Seed
- Geography: United States, France, Denmark
Investor stats
- Total investments: 22
- Round size: Seed $3.4M–$20M; Series A $6.8M–$48M
- Lead/follow: 14% lead, 86% follow
Portfolio highlights
- EvodiaBio — EvodiaBio is a bio-industrial firm that creates natural, sustainable scents for the food and beverage industries. Founded in 2021 and is based in Copenhagen, Capital Region.
- uFraction8 — Multi-award-winning, innovative, microfluidics-based filter systems to provide bio-manufacturers with energy-efficient & ultra-scalable bioprocessing systems.
- Switch Bioworks — Switch Bioworks engineers symbiotic microbes to produce sustainable nitrogen fertilizer under the control of precise genetic circuits.
FundersClub focuses on Seed and early stage investments. Investments include Coinbase, Instacart, Flexport, Le Tote, Teespring, Memebox, GitLab.FundersClub is the world's first online venture capital platform. Backed by Y Combinator, First Round Capital, Spark Capital, Intel Capital, Draper, Andreessen Horowitz, Felicis Ventures, and more;FundersClub Inc. was founded in 2012 and is based in the United States.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, SaaS
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, Canada, India
Investor stats
- Total investments: 353
- Round size: Seed $843k–$5.4M; Pre-Seed $450k–$1.7M; Series A $5M–$23M
- Lead/follow: 6% lead, 94% follow
- Last fund: May invest from a new fund soon — raised $448k in 2019
Portfolio highlights
- Purse — The biggest challenge to Bitcoin commerce is the lack of consumer incentive to spend. Purse generates this incentive in the form of 15% discounts on Amazon. Buyers can purchase bitcoins with a credit card as easily as checking out on Amazon, thus solving the last mile problem.
- Scape — Scape is an AI email client that proactively drafts replies and surfaces what matters. Built for professionals who live in their inbox.
- Gecko Robotics — To collect and make useful physical data in order to protect civilization's most critical infrastructure
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 192
- Round size: Series A $3.7M–$100M; Series B $15M–$114M; Series C $22M–$175M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Arch Oncology — Formerly Known as Vasculox. Tioma is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. The company's functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses.
- Aileron Therapeutics — Aileron Therapeutics - ALRN-6924 - myelopreservation
- AGTC — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Grant, Series C
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 124
- Round size: Grant $1.6M–$10M; Series C $10M–$127M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $319M in 2018
Portfolio highlights
- Lario Therapeutics — Lario Therapeutics is a biopharmaceutical firm that develops precision therapeutics for epilepsy and neurological disorders.
- Wysa — Use Wysa to vent or just talk through negative thoughts and emotions. Let it help you cope with pandemic anxiety and lockdowns. It is anonymous, safe and free.
- Ineffable Intelligence — Ineffable Intelligence develops machine learning systems that learn through interaction and experience. The company works on reinforcement learning approaches that allow models to improve by trial and error rather than relying on large human-generated datasets. Its core work centers on building a “superlearner,” a system designed to generateknowledge and skills by engaging with simulated or real environments.The organization develops algorithms and computational frameworks that support autonomous learning, experimentation, and decision-making processes. Its efforts involve designing AI models that can adapt, refine behavior, and solve complex problems through continuous feedback loops. The company’s research aims to expand how AI systems acquire knowledge and apply it across different domains.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Steen Riisgaard
Show more...Investment focus
- Industry: Life Science, Therapeutics, Biotechnology
- Stage:Pre-Seed
- Geography: Denmark
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
- Synamics Therapeutics — Synamics Therapeutics uses AI and predictive modeling for precision oncology and improved drug discovery. Our adaptive medicine approach helps prolong drug effectiveness and improves outcomes for patients with intractable cancers. Learn more about Synamics Therapeutics and how we leverage AI for personalized, adaptive cancer therapies.
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 171
- Round size: Seed $2.4M–$22M; Series A $5.6M–$49M; Series B $15M–$100M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
- Future Fertility — OUR AI-POWERED ASSESSMENTS GUIDE PERSONALIZED FERTILITY TREATMENT DECISIONS IN OVER 180 CLINICS ACROSS 32 COUNTRIES
- ApoGen Biotechnologies — ApoGen Biotechnologies, Inc. is focused on the development of new class of therapeutics targeting drivers of cancer genomic mutation.As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant nearly all cancer drug therapieseventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival.
In the two decades since our founding, we have worked with hundreds of extraordinary European founders, and have raised eight funds totalling more than $3bn.
Show more...Investment focus
- Industry: Software, FinTech, Financial Services
- Stage:Series A, Series B, Series C
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 340
- Lead/follow: no public data
Portfolio highlights
- Agave Games — Agave Games is a mobile games publishing company and provides unique experiences
- Grand Games — Grand Games is shaping the future of gaming by creating genre-defining games played by millions worldwide.
- Lindus Health — Lindus Health. From recruitment to delivery, we accelerate clinical trials. Our mission is to make health research accessible for everyone, everywhere.
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1475
- Lead/follow: no public data
Portfolio highlights
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- NovoNutrients — NovoNutrients is working to turn waste CO2 into high-value, low-cost proteins and additives for food and feed by developing proprietary microbes and advanced gas fermentation systems.
- Sodex Innovations — Sodex Innovations is a company which is specialized in developing assistance-systems and automating-kits for excavators
+ND Capital (NanoDimension) is a venture capital firm founded in 2002 that invests in disruptive technologies across the life, physical, and data sciences.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series C, Series A
- Geography: United States, Switzerland, Denmark
Investor stats
- Total investments: 58
- Lead/follow: no public data
Portfolio highlights
- Vandria — At the vanguard of Mitochondrial research
- Constructive Bio — Constructive is a ground-breaking method for creating wholly artificial genomes and rewriting the genetic code of living things.
- PulseSight Therapeutics — PulseSight is an ophthalmology drug development company creating novel, non-viral gene therapies with minimally invasive delivery technology to address the unmet need for treatments against severe retinal diseases leading to blindness.
byFounders is the community-powered early-stage venture fund investing in globally ambitious teams connected to the Nordic and Baltic countries. With its unique Collective of founders and operators, byFounders offers its portfolio operational expertise and a global network. Believing in the power of tech to shape our future, byFounders takes an impact-aware approach to investing and working with the broader startup ecosystem.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Pre-Seed, Series A
- Geography: Denmark, United States, Sweden
Investor stats
- Total investments: 124
- Round size: Seed $1.5M–$9.4M; Pre-Seed $800k–$4.2M; Series A $6.1M–$65M
- Lead/follow: 51% lead, 49% follow
- Last fund: May invest from a new fund soon — raised $117M in 2021
Portfolio highlights
- Visoid — Render your 3D models with ease! Quick and easy rendering software for architects, powered by AI. Try Visoid for free!
- Verda (formerly DataCrunch) — DataCrunch is a cloud service provider which facilitates utilization and integration of state of the art AI/ML models
- Spiral Hydrogen — All-in-one, bubble-free centrifugal electrolyzer with an embedded axial flux generator that sets a new standard in efficiency and simplicity.
Targeting critical European re-industrialisation technology across pioneering hardware sectors with capital efficient growth investments.
Show more...Investment focus
- Industry: Energy, Energy Storage, Manufacturing
- Stage:Seed, Series A
- Geography: Denmark, Germany, Sweden
Investor stats
- Total investments: 27
- Round size: Seed $3M–$8.7M; Series A $15M–$15M
- Lead/follow: 70% lead, 30% follow
- Last fund: May invest from a new fund soon — raised $148M in 2017
Portfolio highlights
- Re-Match — Developer of a recycling technology intended to separate synthetic turf into raw components. The company's technology is based upon a mechanical separation which can recycle the entire turf system while avoiding waste products, enabling organizations to dispose of the old turf in an environmentally friendly way and save money at the same time.
- Green Hydrogen Systems — GreenHydrogen believes that electrolysers have a great potential to become a core technology in green and renewable energy.
- Hybrid Greentech — Hybrid Greentech offers end-to-end profitable solutions for BESS projects, from detailed business case and sizing analysis to project development services, EPC management, and operations and optimization for multi-market revenue stacking.
Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: Switzerland, Germany, France
Investor stats
- Total investments: 285
- Round size: Seed $1.4M–$11M; Series A $2.3M–$18M; Series B $4.2M–$45M
- Lead/follow: 13% lead, 87% follow
- Last fund: Likely still investing — raised $66M in 2022
Portfolio highlights
- Axelera AI — Axelera AI is a company that delivers purpose-built hardware and software platforms designed to accelerate artificial intelligence tasks, particularly in edge computing. The company's flagship product, the Metis™ AI Platform, integrates both hardware and software components to deliver high-performance, energy-efficient AI inference solutions.This platform has been recognized for its innovation, notably being named a CES® 2024 Innovation Awards Honoree.Incubated in 2019 by the emerging technologies leader Bitfury and joined by the leading nano-technology group imec in early 2020, Axelera AI launched as a new company in 2021. Headquartered in the AI Innovation Center of the High Tech Campus in Eindhoven, Axelera AI has R&D offices in Belgium, Switzerland, and Italy. Its team of experts in AI software and hardware hail from top AI firms and Fortune 500 companies.
- Aylight — Aylight develops semiconductor laser and photonics platforms designed to improve optical connectivity in AI datacenters and related infrastructure. The company focuses on frequency modulated comb laser technology that generates multiple stable wavelengths from a single InP-based laser cavity. Its architecture produces an equidistant, RF-lockedwavelength grid that aligns with dense wavelength-division multiplexing requirements and reduces control complexity and power consumption. Aylight targets use cases in AI datacenter interconnects, quantum computing hardware, precision metrology, and communication equipment. Its products aim to integrate with terabit optical links and wavelength-division multiplexing systems while remaining compatible with existing fabrication processes.
- Atana Elements — Atana is a data-driven resource company that accelerates the exploration and development of flowing critical minerals.
Seventure Partners is a French venture capital firm targeting in Tech/Digital and Life Sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with € 1 billion undermanagement as of December 31, 2023. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.The different funds/verticals on which Seventure Partners are focusing on today: - Life Sciences : Biotech, Healthcare, Nutrition - Tech/Digital : B2B SaaS, Fintech, Retailtech, Cybersecurity - Sports & Wellbeing - Blue Economy
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series A, Series B
- Geography: France, United States, Germany
Investor stats
- Total investments: 247
- Round size: Series A $3.3M–$28M; Series B $3.4M–$63M
- Lead/follow: 36% lead, 64% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Ekstere — Ekstere facilitates selling and purchasing verified-quality used bicycles at a reasonable price.
- Pitchy — Create professional videos without technical expertise. Our online video editor helps you easily make business videos.
- Presto Engineering — We enable companies imagine and implement microelectronics solutions in high-value markets such as Industrial, Automotive, Communication and Medical.
We invest in disruptive and encouraging Agri-Food tech and Food Loss companies, reshaping our food systems in order to solve the current & future problems of production.
Show more...Investment focus
- Industry: Biotechnology
- Stage:Seed
- Geography: Denmark
Investor stats
- Total investments: 4
- Lead/follow: no public data
Portfolio highlights
- EvodiaBio — Mirroring nature with pioneering bioscience for natural flavors
- Yeastup — Yeastup transforms brewer's yeast into proteins & fibers for food & supplements. Contact us for sustainable ingredient solutions.
- New School Foods — Salmon, made from plants. Clean label with ALL the Omega-3s, NONE of the mercury. Made in Canada.
Biotech Investor funding in Denmark at a glance
Stats across 398 deals from 376 investors.
Access all 376 investors in Denmark Biotech startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotech Investors in Denmark investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 376 investors investing in Denmark Biotech startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!